Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Legal guardian(s) must provide informed consent prior to any study procedures~* Documented diagnosis of severe HPP as indicated by:~  * Total serum alkaline phosphatase at least 3 standard deviations (SD) below the mean for age~ * Plasma pyridoxal 5'-phosphate (PLP) at least 4 times the upper limit of normal~ * Radiographic evidence of HPP (hypophosphatasia), characterized by:~    * Flared and frayed metaphyses~   * Severe, generalized osteopenia~   * Widened growth plates~ * One or more HPP-related findings:~    * History or presence of:~      * Non-traumatic post-natal fracture~     * Delayed fracture healing~   * History of elevated serum calcium~   * Functional craniosynostosis with decreased head circumference growth~   * Nephrocalcinosis~   * Respiratory compromise~ * Rachitic chest deformity and/or vitamin B6 dependent seizures~ * Failure to thrive~* Onset of symptoms prior to 6 months of age~* Age ≤ 36 months~* Otherwise medically stable (patient may be on ventilatory support)~* Legal guardian(s) must be willing to comply with the study~Exclusion Criteria:~* History of sensitivity to any of the constituents of the study drug~* Current or prior clinically significant cardiovascular, endocrinologic, hematologic, hepatic, immunologic, metabolic, infectious, urologic, pulmonary, neurologic, dermatologic, renal condition and/or other major disease which, in the opinion of the investigator, precludes study participation~* Treatment with an investigational drug within 1 month prior to the start of study drug administration~* Current enrollment in any other study involving an investigational new drug, device or treatment for HPP (e.g., bone marrow transplantation)~* Low serum calcium, phosphate or 25(OH) vitamin D~* Current evidence of a treatable form of rickets~* Prior treatment with bisphosphonate

- Gender: ALL
- Minimum Age: None
- Maximum Age: 36 Months
- Healthy Volunteers: f

Study Arms:
- asfotase alfa (Type: OTHER): asfotase alfa

Based on this trial design, predict the completion outcome and termination type (if applicable).